Merck discontinues Phase 3 trial for lung cancer combo drug
When compared to patients in the control arm, patients in the vibostolimab and pembrolizumab fixed-dose combination arm…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.